Opdualag
(Relatlimab)Phase 3Monoclonal antibody
Bristol-Myers SquibbRelatlimab is used to treat a type of skin cancer called melanoma. It works by boosting the immune system to help the body fight cancer cells.[1] Opdualag is currently being investigated across 16 indications[3], with its most advanced program in Phase 3.[1]
Opdualag is one of 329 biologic programs targeting Gastric Cancer. It is currently in Phase 3.
16
Indications
51
Total Trials
24
Active Trials
328
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 16 indications
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Verzenio
Eli LillyPhase 3
Opdualag
Bristol-Myers SquibbPhase 3
Carboplatin Plus Paclitaxel
BayerPhase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Metastatic Melanoma4 trials
Melanoma4 trials
Immunotherapy3 trials
Non-Small Cell Lung Cancer3 trials
Nivolumab3 trials
Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03607890·38 enrolled
31 more indications
Liver Cancer2 trials
Gastric Cancer2 trials
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric Cancer
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT03610711·21 enrolled
Ovarian Cancer1 trial
Effectiveness1 trial
Patients With Solid Tumors1 trial
Mismatch Repair Deficiency1 trial
Esophageal Cancer1 trial
Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT03044613·32 enrolled
Relapsed/Refractory B-cell Malignancies1 trial
Uveal Melanoma1 trial
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
Completed·—·Phase 2·NCT04552223·27 enrolled
Colorectal Cancer1 trial
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT03642067·59 enrolled
Hepatocellular Carcinoma1 trial
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)
Active, not recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT04658147·31 enrolled
Basal Cell Carcinoma1 trial
Renal Cell Carcinoma1 trial
Patients With Advanced Solid Tumors1 trial
Virus-associated Tumors1 trial
Muscle Invasive Bladder Urothelial Carcinoma1 trial
Newly Diagnosed Glioblastoma1 trial
Metastatic Nasopharyngeal Carcinoma1 trial
Head and Neck Squamous Cell Carcinoma (HNSCC)1 trial
High Grade Glioma1 trial
Glioblastoma Multiforme1 trial
Melanoma (Skin)1 trial
Urologic Neoplasms1 trial
Lymphoma, Non-Hodgkin1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Relatlimab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Lymphocyte Activation Gene 3 Protein Inhibitor[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company